semaglutide liver fat reduction CDSCO Clears Wegovy for MASH — India's First GLP-1 Approval for Disease, India's drug regulator CDSCO approved Novo Nordisk's Wegovy (semaglutide 2.4mg) on 17 July 2026 for MASH, based on Wegovy Treated Severe Liver Disease

That foundation is the 40:1 myo-inositol to D-chiro-inositol ratio, which has direct PCOS RCT evidence behind it for ovulatory function and insulin sensitivity (Nordio & Proietti 2012

Biophysics 79 (2), 337347

You're not poisoning yourselfcopper toxicity from peptide dosing is essentially impossible at research concentrationsbut you are wasting 4050% of each dose through competitive inhibition and renal excretion

However, these widely used assays have not been designed to identify HCV subtypes other than 1a and 1b, nor to recognized mixed genotype/subtype infections

Injecting into a nodule produces unpredictable absorption, which means your carefully calibrated dose might deliver half or double the intended effect